Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis
Pharmaceuticals · 07.09.2023 · 16 (9) · 1270
DOI: 10.3390/ph16091270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 07.09.2023. Verfasst von Masaki Gomi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-0856,…. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency, Japan Society for the Promotion of Science, Canon Foundation Research Grant Program.
Abstract (Originalsprache)
Multiple sclerosis is a disease caused by autoantigen-responsive immune cells that disrupt the myelin in the central nervous system (CNS). Although immunosuppressive drugs are used to suppress symptoms, no definitive therapy exists. As in the experimental autoimmune encephalitis (EAE) model of multiple sclerosis, a partial sequence of the myelin oligodendrocyte glycoprotein (MOG35–55) was identified as a causative autoantigen. This suggests that the induction of immune tolerance that is specific to MOG35–55 would be a fundamental treatment for EAE. We previously reported that lipid nanoparticles (LNPs) containing an anionic phospholipid, phosphatidylserine (PS), in their lipid composition, can be used to deliver mRNA and that this leads to proteins of interest to be expressed in the spleen. In addition to the targeting capability of PS, PS molecules avoid activating the immune system. Physiologically, the recognition of PS on apoptotic cells suppresses immune activation against these cells by releasing cytokines, such as interleukin-10 (IL-10) and transforming growth factor (TGF)-β that negatively regulate immunity. In this study, we tested whether mRNA delivery of autoantigens to the spleen by PS-LNPs causes the expression of MOG35–55 antigens with minimal immune stimulation and whether this could be used to treat an EAE model by inducing immune tolerance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-0856, Japan.
- Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
- Life Science Research Laboratory, NOF CORPORATION, 3-3, Chidoricho, Kawasaki-ku, Kawasaki 210-0865, Japan.
ORCID-Profile: Yu Sakurai, Hidetaka Akita
Förderung
- Japan Science and Technology Agency
- Japan Society for the Promotion of Science
- Canon Foundation Research Grant Program
- JST CREST
- JSPS KAKENHI
Zitieren
APA
Gomi, M., Nakayama, Y., Sakurai, Y., Oyama, R., Iwasaki, K., Doi, M., Liu, Y., Hori, M., Watanabe, H., Hashimoto, K., Tanaka, H., Tange, K., Nakai, Y., & Akita, H. (2023). Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis. Pharmaceuticals, 16(9), 1270. https://doi.org/10.3390/ph16091270
Vancouver
Gomi M, Nakayama Y, Sakurai Y, Oyama R, Iwasaki K, Doi M, et al. Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis. Pharmaceuticals. 2023;16(9):1270. doi:10.3390/ph16091270
BibTeX
@article{Gomi2023,
author = {Gomi, Masaki and Nakayama, Yuka and Sakurai, Yu and Oyama, Ryotaro and Iwasaki, Koki and Doi, Mizuki and Liu, Yi and Hori, Mizuho and Watanabe, Himeka and Hashimoto, Kohei and Tanaka, Hiroki and Tange, Kota and Nakai, Yuta and Akita, Hidetaka},
title = {Tolerogenic Lipid Nanoparticles for Delivering Self-Antigen mRNA for the Treatment of Experimental Autoimmune Encephalomyelitis},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {9},
pages = {1270},
doi = {10.3390/ph16091270}
}
EUVIMED